The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Twist Bioscience Corp’s stock clocked out at $39.55, down -3.44% from its previous closing price of $40.96. In other words, the price has decreased by -$3.44 from its previous closing price. On the day, 0.67 million shares were traded. TWST stock price reached its highest trading level at $41.55 during the session, while it also had its lowest trading level at $39.36.
Ratios:
To gain a deeper understanding of TWST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.91. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on June 04, 2024, initiated with a Buy rating and assigned the stock a target price of $53.
On January 17, 2024, Goldman Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $25 to $45.
On September 27, 2023, Berenberg started tracking the stock assigning a Buy rating and target price of $27.Berenberg initiated its Buy rating on September 27, 2023, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 23 ’24 when WERNER ROBERT F. sold 813 shares for $43.14 per share. The transaction valued at 35,074 led to the insider holds 38,964 shares of the business.
WERNER ROBERT F. bought 813 shares of TWST for $35,075 on Aug 23 ’24. On Aug 05 ’24, another insider, Cho Dennis, who serves as the insider of the company, sold 709 shares for $39.93 each. As a result, the insider received 28,308 and left with 78,996 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 2317076224 and an Enterprise Value of 2197442816. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.85 while its Price-to-Book (P/B) ratio in mrq is 4.71. Its current Enterprise Value per Revenue stands at 7.444 whereas that against EBITDA is -14.026.
Stock Price History:
Over the past 52 weeks, TWST has reached a high of $60.90, while it has fallen to a 52-week low of $14.42. The 50-Day Moving Average of the stock is -19.07%, while the 200-Day Moving Average is calculated to be 0.45%.
Shares Statistics:
It appears that TWST traded 1.04M shares on average per day over the past three months and 644190 shares per day over the past ten days. A total of 57.56M shares are outstanding, with a floating share count of 56.07M. Insiders hold about 4.30% of the company’s shares, while institutions hold 106.35% stake in the company. Shares short for TWST as of 1723680000 were 9210027 with a Short Ratio of 8.81, compared to 1721001600 on 9530323. Therefore, it implies a Short% of Shares Outstanding of 9210027 and a Short% of Float of 20.53.
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.44 and low estimates of -$0.76.
Analysts are recommending an EPS of between -$2.87 and -$3.76 for the fiscal current year, implying an average EPS of -$3.54. EPS for the following year is -$2.41, with 12.0 analysts recommending between -$1.97 and -$2.76.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $82.2M. It ranges from a high estimate of $83.6M to a low estimate of $78M. As of the current estimate, Twist Bioscience Corp’s year-ago sales were $66.95MFor the next quarter, 10 analysts are estimating revenue of $85.27M. There is a high estimate of $91.27M for the next quarter, whereas the lowest estimate is $81M.
A total of 12 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $312M, while the lowest revenue estimate was $310.06M, resulting in an average revenue estimate of $310.93M. In the same quarter a year ago, actual revenue was $245.11MBased on 12 analysts’ estimates, the company’s revenue will be $373.19M in the next fiscal year. The high estimate is $400.37M and the low estimate is $352M.
